EXPRESS MAIL" MAILING LABEL NO. EL808219641US
DATE MAILED: 18 DECEMBER 2001

Attorney Docket No.: P30919X1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	F.W. Grimmett, *et al.*	18 December 2001
Div of Serial No.:	09/640,823	Group Art Unit: Not Assigned
Filed:	Herewith	Examiner: Not Assigned
For:	PHARMACEUTICAL FORMULATION	

PRELIMINARY AMENDMENT

Prior to calculating the filing fee and examination of the application on the merits, entry of the followings amendments and remarks into the record is respectfully requested.

In the Specification:

Change the title to -- TABLET CONTAINING A COATED CORE -- .

In the Claims:

Please cancel claims 1 to 5 and 10 to 15.

6 (amended). A tablet formulation according to Claim 16 wherein the core and the casing layer both comprise a compact of compressed ingredients including the respective active materials.

7 (amended). A tablet formulation according to Claim 16 wherein the release retarding coating is an enteric polymer.

8 (amended). A tablet formulation according to Claim 16 further comprising one or more sub-coats beneath the release retarding coating layer.

9 (amended). A tablet formulation according to Claim 16 further comprising one or more over-coats above the release retarding coating layer.

Please amend the following claims:
Please add the following new claims 16-18:

16. A tablet formulation for oral administration comprising amoxycillin and clavulanate in a ratio of 30:1 to 1:1 in which a portion of the amoxycillin and a portion of the

clavulanate is in a central core which is surrounded by a release-retarding coating layer and the remainder of the amoxicillin and the remainder of the clavulanate is in a casing layer surrounding the core, such that there is an initial quick release of amoxycillin and clavulanate from the casing layer and a sustained release of amoxycillin and clavulanate from the core.

17. A tablet formulation according to Claim 16 for oral administration twice a day.

18. A method of treating a bacterial infection in a patient in need thereof, which method comprises administering to said patient an effective amount of a formulation according to Claim 16.

REMARKS

Claims 1 to 5, and 10 to 15 have been cancelled. Claims 6 to 9 have been amended. Claims 16 to 18 have been added. Support for the newly added claims lies in the specification on page 2, lines 22 to 32. No new matter is believed added.

A title more descriptive of the claimed invention has been provided.

An abstract of the disclosure as required by 37 C.F.R. 172(b) is enclosed. Also, enclosed is the formal drawing for this application.

Favorable consideration of this application is respectfully requested.

Respectfully submitted

Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property-US UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Telephone: (610)270-5017
Facsimile: (610)270-5090
\301919\919X1D2

MARKED VERSION TO SHOW CHANGES MADE

The following claims have been amended:

6 (amended). A tablet formulation according to [any one of the preceding claims characterised in that] Claim 16 wherein the core and the casing layer both comprise a compact of compressed ingredients including the respective active materials.

7 (amended). A tablet formulation according to [any one of the preceding claims characterised in that] Claim 16 wherein the release retarding coating is an enteric polymer.

8 (amended). A tablet formulation according to [any one of the preceding claims having] Claim 16 further comprising one or more sub-coats beneath the release retarding coating layer.

9 (amended). A tablet formulation according to [any one of the preceding claims having] Claim 16 further comprising one or more over-coats above the release retarding coating layer.